The deal is Eli Lilly’s latest attempt to capitalize on the weight loss industry gold rush, which was sparked by demand for Novo Nordisk’s Wegovy and Ozempic.The deal is Eli Lilly’s latest attempt to capitalize on the weight loss industry gold rush, which was sparked by demand for Novo Nordisk’s Wegovy and Ozempic.
